Data Collective IV GP, LLC Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001664974

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedTechnology TiltBuy & Hold how tags are computed

Q2 2026 · 4 positions · Total reported value $78.55M · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 0.0% · 0 new · 0 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q2 2026 13F filing, Data Collective IV GP, LLC disclosed 4 equity positions with a combined reported value of $78.55M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Technology Tilt / Buy & Hold.

The largest disclosed positions as of Q2 2026 were EVLV ($26.62M), HQ ($25.41M), RXRX ($21.80M). By sector, the heaviest allocations are Technology 66.2%, Health Care 33.8%. Versus the prior quarter, allocation shifted toward Technology (+2.2pp) and away from Health Care (-2.2pp).

Versus the prior quarter, Data Collective IV GP, LLC opened 0 new positions, trimmed 0 and fully exited 0, a turnover rate of 0.0% of positions. The portfolio's overlap with the prior quarter was 100% of names.

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

Insider Transactions (Form 4)

Latest Data Collective IV GP, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Data Collective IV GP, LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 4 positions worth $78.55M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 4 positions · $78.55M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: EVLV (EVOLV TECHNOLOGIES HLDNGS INC COM CL A) at 33.9%
  • Average position size: $19.64M

Sector Tilt

  • Information Technology 66.2%
  • Health Care 33.8%
  • (classified holdings cover 100% of value)

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The Data Collective IV GP, LLC fund maintained its positions in the second quarter of 2026, indicating a conservative stance with a preference for stability and long-term growth. The lack of new additions suggests a focus on existing investments rather than seeking new opportunities in the market. 2. Key Moves: - No New Positions: The fund did not add any new positions in the quarter, which aligns with a conservative strategy. - No Reductions: There were no reductions in existing positions, suggesting a commitment to the current portfolio composition. 3. Portfolio Structure: - Passive/Active: The fund appears to be passive in nature, as it held onto its positions without significant changes. - Sector Bias: The portfolio is heavily biased towards Technology and Health Care sectors, reflecting a focus on innovation and biopharmaceuticals. - Risk Appetite: The risk appetite is moderate, as indicated by the conservative stance and the absence of aggressive moves. 4. Per-Holding One-Liner: - EVLV (EVOLV TECHNOLOGIES HLDNGS INC): A technology holding; 'unverified' - HQ (HORIZON QUANTUM HOLDINGS LTD): A technology holding; 'unverified' - RXRX (RECURSION PHARMACEUTICALS INC): A biopharmaceutical company focusing on the development of novel therapies; 'unverified' - DFTX (DEFINIUM THERAPEUTICS INC COM): A biopharmaceutical company focused on the development of therapies for rare diseases; 'unverified' 5. One-Sentence Style Summary: The Data Collective IV GP, LLC maintained a stable, passive portfolio with a strong focus on technology and health care sectors, reflecting a conservative investment strategy with a preference for long-term growth.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Technology 66.2%
Health Care 33.8%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 4.59M $26.62M 33.89%
33.89%
Hold
2 915.20K $25.41M 32.34%
32.34%
Hold
3 5.94M $21.80M 27.76%
27.76%
Hold
4 100.35K $4.72M 6.01%
6.01%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 100% R 100% F1 100% (modelled on 2026-Q1; 4/10 hit)

Historical Backtest (10 quarters)

Avg precision 90% · recall 93% · F1 91% · avg rank error 1.6 · Top-10 turnover 9%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 100% 100% 100% RXRX · EVLV · RKLB · MNMD · ROIV RXRX · EVLV · RKLB · MNMD · ROIV
2024-Q2 100% 83% 91% RXRX · EVLV · RKLB · MNMD · ROIV OKLO · RXRX · EVLV · RKLB · MNMD · ROIV
2024-Q3 100% 100% 100% OKLO · RXRX · EVLV · RKLB · MNMD · ROIV OKLO · EVLV · RXRX · RKLB · MNMD · ROIV
2024-Q4 100% 100% 100% OKLO · EVLV · RXRX · RKLB · MNMD · ROIV OKLO · RXRX · EVLV · RKLB · MNMD · ROIV
2025-Q1 83% 100% 91% OKLO · RXRX · EVLV · RKLB · MNMD · ROIV RXRX · EVLV · RKLB · MNMD · ROIV
2025-Q2 100% 100% 100% RXRX · EVLV · RKLB · MNMD · ROIV EVLV · RKLB · RXRX · MNMD · ROIV
2025-Q3 80% 100% 89% EVLV · RKLB · RXRX · MNMD · ROIV EVLV · RXRX · MNMD · ROIV
2025-Q4 75% 100% 86% EVLV · RXRX · MNMD · ROIV EVLV · RXRX · MNMD
2026-Q1 67% 50% 57% EVLV · RXRX · MNMD EVLV · RXRX · HQ · DFTX
2026-Q2 ★ 100% 100% 100% EVLV · RXRX · HQ · DFTX EVLV · HQ · RXRX · DFTX

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Data Collective IV GP, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Data Collective IV GP, LLC reported 4 equity positions worth $78.55M in aggregate; its largest disclosed positions were EVLV ($26.62M), HQ ($25.41M), RXRX ($21.80M).

How large is Data Collective IV GP, LLC's portfolio?

Data Collective IV GP, LLC reported $78.55M of long equity holdings across 4 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is Data Collective IV GP, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Technology Tilt / Buy & Hold, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/data-collective-iv-gp/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →